Merck & Co., Inc. (MRK) News Today

Merck & Co., Inc. (NYSE: MRK) is trading higher overall, supported by positive regulatory and pipeline developments, although the voluntary withdrawal of a lung-cancer application and safety concerns surrounding an eye-drug candidate are limiting sentiment.

• Positive Sentiment: The FDA approved WELIREG (belzutifan) in combination with LENVIMA for certain previously treated adults with advanced clear-cell renal cell carcinoma. The expanded indication could increase WELIREG’s commercial opportunity and strengthen Merck’s oncology portfolio. FDA approves WELIREG plus LENVIMA
• Positive Sentiment: Merck’s WINREVAIR label was updated to include evidence from newly diagnosed pulmonary arterial hypertension patients, potentially broadening physician confidence and future adoption of the therapy. Merck jumps as Winrevair moves earlier in PAH
• Positive Sentiment: Remigromig met the primary endpoint in the BRUNELLO diabetic macular edema study by demonstrating non-inferiority to ranibizumab. Success in the second pivotal study could create a new ophthalmology growth opportunity for Merck. Remigromig meets main goal in diabetic macular edema study
• Neutral Sentiment: RBC Capital maintained its Hold rating, signaling no new change in its view of MRK’s valuation or outlook. RBC Capital maintains Hold rating
• Negative Sentiment: Merck and Daiichi Sankyo voluntarily withdrew the U.S. accelerated-approval application for ifinatamab deruxtecan in previously treated extensive-stage small-cell lung cancer following discussions with regulators. The decision removes a near-term regulatory catalyst and raises uncertainty around the drug’s development path. Merck and Daiichi Sankyo withdraw lung-cancer drug application
• Negative Sentiment: Although remigromig achieved its efficacy goal, reports cited higher rates of certain retinal complications. Additional safety analysis and results from the second pivotal study remain important before the treatment’s commercial potential can be assessed. Remigromig trial raises safety concerns